Retrospective Study Of The Effect Of Intravesical Chemotherapy On Postoperative Prognosis Of Patients With Papillary Urothelial Neoplasms Of Low Malignant Potential

Objectives:To investigate the 30mg theprubicin Bladder Intravesical Chemotherapy in Adjuvant Therapy After Transurethral resection of Bladder tumor whether it can significantly reduce Bladder papillary urothelial neoplasms of low malignant potential postoperative recurrence probability.And observe the clinical effect of the treatment of30mg theprubicin Immediately and 30mg theprubicin on the maintenance of Bladder Intravesical Chemotherapy in Adjuvant Therapy After Transurethral resection of Bladder tumor.Methods:Selection of 99 cases admitted in the first hospital of jiaxing and the second hospital of jiaxing during 2008.01-2016.01 PUNLMP patients,According to the study sample inclusion criteria,71 cases of PUNLMP patients meet the standard were divided into single TURB-t group?group A?,the TURB-t postoperative immediate perfusion group?group B?,TURB-t postoperative maintain perfusion group?group C?,according to the different treatment.after long time follow-up,To analyze the differences of clinical outcomes in three groups of PUNLMP patientsResults:Among the 71 patients with PUNLMP,12 had recurrent recurrence and the recurrence rate was 16.90%,and the recurrence probability of group A,group B and group C was 38.89%?7 cases/18 cases?,10.71%?3 cases/28 cases?and 8.00%?2/25?.The recurrent PUNLMP patients had 11 cases of recurrence in 5 years,accounting for 91.67%of the total recurrence.The relapsing patients underwent the second TURB-t operation and elected to maintain the Bladder Intravesical Chemotherapy with 30mg pyrroxine.Continue to follow up,There were 2 cases of recurrence in group A,and the recurrence occurred in the 11th and 9th months after the second TURB-t surgery.In group B,1 case recurrence occurred in the 21st month after the second tub-t operation.In group A,1 case of recurrent PUNLMP was confirmed as low grade papillary urothelial carcinoma,and the remaining 2 cases had no progression of tumor grade.The rate of progression of secondary PUNLMP patients to low grade urothelial carcinoma was 33.33%.Group A had statistically significant between group B?X₁²=5.112,P₁=0.033?and group C?X₂²=6.033,P₂=0.023?in the postoperative recurrence rate difference of PUNLMP patients.There was no statistically significant between group B and group C in the postoperative recurrence rate of PUNLMP patients?X₃²=0.114,P₃=1.000?.Conclusions:PUNLMP patients had a higher recurrence rate after surgery,and the recurrence time generally occurred within 5 years after surgery.The incidence of tumor progression in patients with secondary recurrent PUNLMP was 33.33%.The intravesical chemotherapy after TURB-t can decrease recurrence rate and improve the prognosis.The TURB-t combined with theprubicin 30mg immediate intravesical infusion chemotherapy and TURB-t combined with theprubicin 30mg intravesical infusion chemotherapy regimen have little difference in the prognosis of PUNLMP.And from the perspective of alleviating the pain of multiple intravesical instillation chemotherapy and reducing the cost of treatment,it is recommended that The tumor was less than 3cm long and had a single tumor of PUNLMP patients undergoing TURB-t should be treated with intravesical instillation of 30 mg of theprubicin immediately.